Check the shelves of any research (or mad) scientist and you'll likely find Sigma-Aldrich's chemical products. The company is a leading supplier of chemicals to research laboratories. It has more than 100,000 accounts, including labs involved in government and commercial research, for 250,000 chemical and biochemical and 46,000 equipment products it offers in its Sigma, Aldrich, Fluka and Supelco catalogs. It makes about 114,000 of the products it sells. The business derives revenues from two major areas: Research Chemicals (essentials, specialties, and biotech), and Fine Chemicals (commercial applications). In 2015 the company was acquired by Germany-based pharmaceutical giant Merck for $17 billion.
Change in Company Type
As a result of the acquisition, Sigma-Aldrich and Merck's existing life science division, EMD Millipore, began operating as parts of MilliporeSigma.
Sigma-Aldrich operates in 37 countries, and sells its products to about 160 countries worldwide.
The company's three market-focused business units that are defined by the customers and markets they serve are: Research, Applied, and SAFC Commercial.
Research products and services include chemicals, reagents and kits, enable scientists to discover and develop new drugs and materials.
Applied products and services include high quality components and kits, chemical reagents, critical raw materials and certified reference standards, provide customized solutions to and constitute critical components and materials for diagnostic companies, testing laboratories and industrial companies;
SAFC Commercial helps customers develop and manufacture product and services commercial production of pharma, biopharma and electronics products. Products and services include media and critical raw materials for industrial cell culture, contract manufacturing services, pharmaceutical safety testing services, and organometallic precursors for semiconductor manufacturing.
Sales and Marketing
Sigma-Aldrich's sales are divided among government institutions, nonprofits, universities, and pharmaceutical, diagnostic, biotech companies, and individual customers. It also serves chemical companies, electronic companies, and hospitals. It has more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets.
Sigma-Aldrich is looking to improve sales growth by continuing to focus on its customers, while taking advantage of an improved government funding environment and higher growth in emerging markets. To better serve its customers, Sigma-Aldrich also strives to maintain sufficient supplies of its products, routinely ship the same day of order, and provide prompt customer service. It also forms and maintains strategic alliances and distribution arrangements with partners to acquire, maintain, and increase its sales. Sigma-Aldrich seeks growth both organically and through acquisitions.
In 2015 the company’s main focus was to increase geographic coverage, particularly in Asia/Pacific region, pursuing new and innovative technologies and expanding product and service offerings organically and through strategic acquisitions.
That year Sigma-Aldrich opened its Asia/Pacific headquarters and Cell Culture Technical Center in Singapore to support the customers of its SAFC Commercial business in biopharmaceutical development and manufacturing.
In 2015 the company signed a global distribution agreement with Roche. The deal allows the company to provide more customers with access to high-quality Roche Biochemical Reagent products through Sigma-Aldrich's expanded eCommerce and distribution networks.
In 2014 it launched a comprehensive portfolio of more than 600 Flavors and Fragrances calibration standards and Certified Reference Materials aimed at the food and beverage and cosmetic markets to better ensure product quality and safety. The new organic compounds are designed for analytical instrument calibration, an important role in determining the composition of consumables.
Mergers and Acquisitions
In 2015 Sigma-Aldrich acquired the Duolink product portfolio from Olink Bioscience. The acquisition included intellectual property, sales, marketing and manufacturing assets. The newly acquired product line is designed for researchers studying biological pathways and seeking improved sensitivity to uncover disease biomarkers.
In 2014 the company acquired California-based Cell Marque, an industry-leading provider of in vitro diagnostic (IVD) antibody reagents and kits. Cell Marque's products and technical expertise, include validated, fit-for-purpose antibodies and IHC staining kits aimed at pathologists and clinicians focused on patient management.